Skip to main content
Fig. 3 | SpringerPlus

Fig. 3

From: Characteristics of safety information obtained from postmarketing observational studies for re-examination in Japan

Fig. 3

Relationship between: the difference of incidence rate of the most common adverse reaction in clinical studies for NDA and that in PMO studies; and the difference of the overall adverse reaction rate in clinical studies for NDA and that in PMO studies (162 drug products, 192 sets). Vertical axis difference of the overall adverse reaction rate in clinical studies for NDA and that in PMO studies for re-examination (ARR-NDA–ARR-PMO). Horizontal axis difference of incidence rate of the most common adverse reaction in clinical studies for NDA and that in PMO studies for re-examination

Back to article page